[go: up one dir, main page]

MX2015013355A - Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. - Google Patents

Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.

Info

Publication number
MX2015013355A
MX2015013355A MX2015013355A MX2015013355A MX2015013355A MX 2015013355 A MX2015013355 A MX 2015013355A MX 2015013355 A MX2015013355 A MX 2015013355A MX 2015013355 A MX2015013355 A MX 2015013355A MX 2015013355 A MX2015013355 A MX 2015013355A
Authority
MX
Mexico
Prior art keywords
claudine
antibodies against
cancer treatment
therapy involving
involving antibodies
Prior art date
Application number
MX2015013355A
Other languages
English (en)
Other versions
MX372883B (es
Inventor
Ugur Sahin
Özlem Türeci
Original Assignee
Tron Translationale Onkologie Ander Universitätsmedizin Der Johannes Gutenberg Universitätmainz Geme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tron Translationale Onkologie Ander Universitätsmedizin Der Johannes Gutenberg Universitätmainz Geme filed Critical Tron Translationale Onkologie Ander Universitätsmedizin Der Johannes Gutenberg Universitätmainz Geme
Publication of MX2015013355A publication Critical patent/MX2015013355A/es
Publication of MX372883B publication Critical patent/MX372883B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona generalmente una terapia para tratar y/o prevenir de manera efectiva enfermedades asociadas con células que expresan CLDN18.2, En particular enfermedades cancerosas tales como cáncer gastroesofágico. Se presentan datos que muestran que la administración del anticuerpo anti-CLDN18.2 a pacientes humanos con cáncer gastroesofágico es segura y bien tolerada hasta una dosis de al menos 1000 mg/m2. Adicionalmente, se presentan datos que muestran que el anticuerpo es completamente funcional en estos pacientes para ejecutar los efectos de células anti-tumor y se obtuvo evidencia para la actividad anti-tumoral.
MX2015013355A 2013-03-18 2014-03-17 Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer. MX372883B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2013/000817 WO2014146672A1 (en) 2013-03-18 2013-03-18 Therapy involving antibodies against claudin 18.2 for treatment of cancer
PCT/EP2014/000719 WO2014146778A1 (en) 2013-03-18 2014-03-17 Therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (2)

Publication Number Publication Date
MX2015013355A true MX2015013355A (es) 2016-06-24
MX372883B MX372883B (es) 2020-07-08

Family

ID=48182875

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013355A MX372883B (es) 2013-03-18 2014-03-17 Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.
MX2020003719A MX2020003719A (es) 2013-03-18 2015-09-18 Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003719A MX2020003719A (es) 2013-03-18 2015-09-18 Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.

Country Status (18)

Country Link
US (3) US10137195B2 (es)
JP (5) JP6416197B2 (es)
KR (3) KR20230015514A (es)
CN (1) CN105189554B (es)
AU (4) AU2014234684B2 (es)
BR (1) BR112015023910B1 (es)
CA (1) CA2899770A1 (es)
DK (1) DK2976360T3 (es)
ES (1) ES2765949T3 (es)
HU (1) HUE048541T2 (es)
IL (3) IL305017A (es)
MX (2) MX372883B (es)
MY (1) MY191040A (es)
PT (1) PT2976360T (es)
RU (1) RU2678700C2 (es)
SG (2) SG10201707684WA (es)
UA (1) UA119036C2 (es)
WO (2) WO2014146672A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
SG11201503593UA (en) 2012-11-13 2015-06-29 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165765A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
CA3030257A1 (en) * 2016-07-08 2018-01-11 Carsgen Therapeutics Co., Ltd. Antibody for anti-claudin 18a2 and use thereof
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019173420A1 (en) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
KR102421427B1 (ko) * 2018-05-18 2022-07-18 라노바 메디신즈 리미티드 컴파니 항-클라우딘 18.2 항체 및 이의 사용
CN111867630B (zh) 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
CN112513093B (zh) * 2018-07-18 2024-08-09 奥美药业有限公司 一种新型抗体及其制备方法和应用
US11692031B2 (en) * 2018-08-03 2023-07-04 Amgen Research (Munich) Gmbh Antibody constructs for CLDN18.2 and CD3
KR20210050547A (ko) * 2018-08-27 2021-05-07 난징 산홈 팔마세우티칼 컴퍼니 리미티드 항-클라우딘18.2 항체 및 이의 용도
WO2020063988A1 (zh) * 2018-09-30 2020-04-02 科济生物医药（上海）有限公司 Cldn18的抗体和化疗药物的联合治疗
SG11202105885WA (en) * 2018-12-07 2021-07-29 Zlip Holding Ltd Anti-claudin antibodies and uses thereof
CN113166246B (zh) * 2018-12-28 2024-10-18 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
AU2020273695B2 (en) * 2019-05-16 2024-10-31 Qilu Pharmaceutical Co., Ltd. Antibody against claudin 18A2 and use thereof
CN111944048B (zh) * 2019-05-16 2023-10-03 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
US20220396616A1 (en) * 2019-05-24 2022-12-15 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
KR102758039B1 (ko) * 2019-05-30 2025-01-22 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 클라우딘(Claudin) 18.2를 표적화하는 항체 또는 키메라 항원 수용체
AU2020313978B2 (en) 2019-07-17 2025-05-15 The Regents Of The University Of California Claudin18 antibodies and methods of treating cancer
WO2021027850A1 (en) * 2019-08-12 2021-02-18 I-Mab Biopharma Co., Ltd. Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
US20220306765A1 (en) * 2019-08-20 2022-09-29 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-cldn18.2 antibodies
CN114981303B (zh) * 2019-09-13 2024-01-23 安徽俊义医疗管理咨询有限公司 人源化抗Claudin18.2（CLDN18.2）抗体
CN112707965A (zh) 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
US20230030674A1 (en) * 2019-12-06 2023-02-02 Sotio Biotech A.S. Humanized cldn18.2 antibodies
KR20230016212A (ko) * 2020-05-25 2023-02-01 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 항-cldn18.2 항체 및 이의 진단 용도
CN113735974B (zh) * 2020-05-29 2023-10-27 杭州邦顺制药有限公司 针对Claudin18.2的抗体及其用途
IL299339A (en) * 2020-06-23 2023-02-01 Antengene Biologics Ltd Antibodies and methods for treating claudin-related diseases
CN111777681B (zh) * 2020-07-06 2022-10-11 康诺亚生物医药科技（成都）有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
JP2023542257A (ja) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
WO2022100590A1 (zh) * 2020-11-10 2022-05-19 齐鲁制药有限公司 针对密蛋白18a2的adcc增强型人源化抗体及其应用
CN114805571B (zh) * 2021-01-28 2023-08-25 广西鹭港生物医药科技有限公司 抗cldn18.2抗体及其应用
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
AU2022326063A1 (en) 2021-08-09 2024-03-14 Harbour Biomed (Shanghai) Co., Ltd Cldn18.2-targeting antibody, bispecific antibody and use thereof
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN119101162A (zh) * 2023-06-07 2024-12-10 江苏奥赛康生物医药有限公司 一种抗cldn18_2的抗体及体外诊断试剂盒
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
CN117701719B (zh) * 2024-02-04 2024-05-31 北京肿瘤医院(北京大学肿瘤医院) 肿瘤靶向cldn18.2治疗耐药标志物及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1144629A3 (en) 1998-09-01 2001-11-28 Genentech, Inc. Further pro polypeptides and sequences thereof
NZ510464A (en) 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
IL142012A0 (en) 1998-09-16 2002-03-10 Zymogenetics Inc Stomach polypeptide zsig28
WO2000020447A2 (en) 1998-10-06 2000-04-13 Curagen Corporation Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
AU3774500A (en) 1999-03-31 2000-10-16 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
EP1251863A4 (en) 2000-01-31 2005-03-02 Human Genome Sciences Inc 22 SEPARATE HUMAN PROTEINS
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1255777A1 (en) 2000-01-31 2002-11-13 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001241417A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
DE60128701T2 (de) 2000-08-15 2008-02-07 Immunex Corp., Thousand Oaks Claudin polypeptide
AU2001286810A1 (en) 2000-08-28 2002-03-13 Diadexus, Inc. Compositions and methods relating to lung specific genes
AU2001294541A1 (en) 2000-09-08 2002-03-22 Schering Corporation Mammalian genes; related reagents and methods
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN1729203B (zh) 2002-10-17 2014-02-19 根马布股份公司 抗cd20的人单克隆抗体
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
EP2182057A1 (en) 2005-08-31 2010-05-05 Cell Signaling Technology, Inc. Antibody agains phosphorylated Tyrosine for the detection of protein phosphorylation in carcinoma signaling pathways
DK2402758T3 (da) 2005-09-19 2014-11-03 Janssen Diagnostics Llc Fremgangsmåder og anvendelser til identificering af oprindelsen af et karcinom med ukendt primær oprindelse
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR101296264B1 (ko) 2006-02-09 2013-08-14 암젠 리서치 (뮌헨) 게엠베하 전이성 유방암의 치료
US20100129929A1 (en) 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
WO2008095152A2 (en) 2007-02-01 2008-08-07 Veridex, Llc Methods and materials for identifying the origin of a carcinoma of unknown primary origin
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JPWO2008152822A1 (ja) 2007-06-15 2010-08-26 株式会社メディネット 医薬
EP2036987A1 (en) 2007-09-17 2009-03-18 Siemens Healthcare Diagnostics GmbH Molecular markers for tumor cell content in tissue samples
WO2010141093A2 (en) 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer

Also Published As

Publication number Publication date
RU2019101923A (ru) 2019-02-22
JP2022133424A (ja) 2022-09-13
MY191040A (en) 2022-05-30
CA2899770A1 (en) 2014-09-25
AU2019201513B2 (en) 2020-08-13
CN105189554A (zh) 2015-12-23
RU2678700C2 (ru) 2019-01-31
US10137195B2 (en) 2018-11-27
HUE048541T2 (hu) 2020-07-28
IL299004A (en) 2023-02-01
UA119036C2 (uk) 2019-04-25
CN105189554B (zh) 2021-10-08
JP7166310B2 (ja) 2022-11-07
US20220184209A1 (en) 2022-06-16
JP7018361B2 (ja) 2022-02-10
US20190076525A1 (en) 2019-03-14
JP6416197B2 (ja) 2018-10-31
IL299004B2 (en) 2024-02-01
IL240060B1 (en) 2023-01-01
RU2015144666A3 (es) 2018-03-26
KR20150130318A (ko) 2015-11-23
WO2014146778A1 (en) 2014-09-25
JP2018184403A (ja) 2018-11-22
ES2765949T8 (es) 2020-06-23
SG10201707684WA (en) 2017-11-29
AU2022246477A1 (en) 2022-11-03
JP2016517447A (ja) 2016-06-16
AU2014234684B2 (en) 2018-12-06
WO2014146672A1 (en) 2014-09-25
KR20240096827A (ko) 2024-06-26
RU2015144666A (ru) 2017-04-21
JP2024056803A (ja) 2024-04-23
AU2022246477B2 (en) 2025-04-17
AU2019201513A1 (en) 2019-03-28
DK2976360T3 (da) 2020-01-27
HK1219486A1 (en) 2017-04-07
MX372883B (es) 2020-07-08
KR102490997B1 (ko) 2023-01-25
JP2020143153A (ja) 2020-09-10
AU2020210165A1 (en) 2020-08-13
AU2014234684A1 (en) 2015-08-20
BR112015023910B1 (pt) 2019-09-10
SG11201507764QA (en) 2015-10-29
AU2020210165B2 (en) 2022-07-14
NZ710648A (en) 2021-03-26
MX2020003719A (es) 2020-07-22
ES2765949T3 (es) 2020-06-11
PT2976360T (pt) 2020-01-22
BR112015023910A2 (pt) 2017-03-21
KR20230015514A (ko) 2023-01-31
US11395852B2 (en) 2022-07-26
IL240060A0 (en) 2015-09-24
IL305017A (en) 2023-10-01
JP7633968B2 (ja) 2025-02-20
IL240060B2 (en) 2023-05-01
US20160008465A1 (en) 2016-01-14
IL299004B1 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
CR20160186A (es) Anticuerpos anti-cd38 específicos para tratar cánceres humanos
NI201200181A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX373187B (es) Terapia de combinación para tratar cáncer.
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
MX2016015346A (es) Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2020001727A (es) Terapia de combinacion.
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SOCIETE DES PRODUITS NESTLE S.A.*

FG Grant or registration
PD Change of proprietorship

Owner name: ASTELLAS PHARMA INC.